Napo Pharmaceuticals

Jaguar Health (NASDAQ:JAGX) company Napo Pharmaceuticals develops and commercializes pharmaceuticals from plants harvested responsibly from rainforest areas.

[Napo Pharmaceuticals @napopharma]

Napo's Parent Company Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 https://t.co/ObI9uqDgdw #JAGX

[Napo Pharmaceuticals @napopharma]

Investigator-Initiated Trial of Crofelemer Yields Positive Results for Functional Diarrhea https://t.co/rUF7DQJ3D5 #JAGX

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals’ Parent Company Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product https://t.co/WlgrWf6GNm #JAGX

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals’ Parent Jaguar Health Reports Q1 2024 Financial Results; Investor Webcast 8:30 a.m. Eastern Today https://t.co/w2deEIQR5S #JAGX

[Napo Pharmaceuticals @napopharma]

REMINDER: Napo Pharmaceuticals' Parent Company Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates https://t.co/pEbzqttU0W #JAGX

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals Parent Company Jaguar Health Announces Submission of Clinical Trial Applications for the Rare Disease Indications Microvillus Inclusion Disease and Short Bowel Syndrome in Europe https://t.co/awBr0t1Abb #JAGX

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals' Parent Company Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates https://t.co/TtGCnwW3hL #JAGX

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) https://t.co/P8Pox9HLYB

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society Congress in Support of Company’s Expanding Focus on Cancer Supportive Care https://t.co/SZ4ZuGjZOl #JAGX

[Napo Pharmaceuticals @napopharma]

Jaguar Health (NASDAQ: JAGX), Napo Pharmaceuticals' Parent Company, Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care https://t.co/OO7l9mGeKI #JAGX

[Napo Pharmaceuticals @napopharma]

Napo's parent Jaguar Health today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi to Direct Relief, a Santa Barbara, California-based humanitarian aid organization. https://t.co/sLBVBqoS1j

[Napo Pharmaceuticals @napopharma]

Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals submitted an Orphan Drug Designation application to the FDA for cholera-related diarrhea. https://t.co/nVPsLhlcMY

[Napo Pharmaceuticals @napopharma]

Dog study published in PLOS ONE shows statistically significant results for our crofelemer prescription drug https://t.co/6zjCi67HSo #crofelemer

[B2i Digital @b2idigital]

Our @b2idigital featured company, @Jaguar_Health (NASDAQ: JAGX), shared an update - the U.S. Patent and Trademark Office issued a new patent for their pipeline drug crofelemer to Jaguar’s subsidiary @napopharma

According to today’s press release, this latest patent provides additional intellectual property protection as Jaguar develops crofelemer for congenital diarrheal disorders (CDDs) like microvillus inclusion disease, an extremely rare condition in infants with no approved treatments.

Jaguar is running clinical trials investigating the potential of crofelemer for microvillus inclusion disease (MVID) and short bowel syndrome (SBS), another rare gastrointestinal disease. Data from these studies is expected later this year.

The company is focused on sustainably developing crofelemer and other pipeline compounds to address neglected gastrointestinal and mental health conditions.

We are pleased to see Jaguar’s continued progress in advancing innovative plant-based prescription drug candidates.

Full Press Release: https://t.co/02yZ51L5Tj

B2i Digital sends our continued good wishes to CEO Lisa Conte, Chief Scientific Officer Pravin Chaturvedi, and the entire Jaguar team, who are on the front lines of scientists discovering new treatments against catastrophic medical situations, such as MVID.

Learn more about Jaguar Health and Napo Pharmaceuticals and stay current on the company and its latest news. Featured Company Profile: https://t.co/Zn5fRI6Npg

#biotech #pharma #rareisease #clinicaltrials #healthtech #B2iDigital #JaguarHealth #CancerCare #QualityOfLife #MVID #SBS

[Napo Pharmaceuticals @napopharma]

Napo Pharmaceuticals, a Jaguar family company, announced that a new US patent has been issued to Napo for methods for treating congenital diarrheal disorders with crofelemer, Napo's novel plant-based prescription drug. https://t.co/uWve4cEej6 #JAGX

[Napo Pharmaceuticals @napopharma]

What does "Supportive Care" mean to you? How might supportive care be improved? Please let us know your thoughts: https://t.co/W2tpuq93MS

#SuppOnc #bcsm #btsm #crcsm #gyncsm #lcsm #mmsm

[Napo Pharmaceuticals @napopharma]

Napo, a Jaguar Health family company, today announced that a majority of subjects in the placebo-controlled pivotal Phase 3 OnTarget trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy chose to continue on to Stage II. https://t.co/7PxlYM6PuA

[Napo Pharmaceuticals @napopharma]

MASCC (Multinational Association of Supportive Care in Cancer) webinar on GI toxicities from cancer therapies made possible by grant from Napo Pharmaceuticals, a Jaguar Health family company https://t.co/WPBbIaPhRs #MASCC

[Napo Pharmaceuticals @napopharma]

Study data on quality of life for breast cancer patients and survivors, supported by Napo Pharmaceuticals (a Jaguar Health family company), published on San Antonio Breast Cancer Symposium (SABCS) website https://t.co/6dSy5K5lLk #sabcs2023

[Napo Pharmaceuticals @napopharma]

Eagerly anticipating San Antonio Breast Cancer Symposium and looking forward to speaking with patients, survivors, and clinicians about what matters to them in cancer care. #SABCS23 #breastcancer